Last $2.64 USD
Change Today -0.08 / -2.94%
Volume 1.3M
VVUS On Other Exchanges
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/29/14 - $7.73
52 Week Low
01/22/15 - $2.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

98 Employees
Last Reported Date: 02/28/14
Founded in 1991

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $212.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $274.8K
Senior Vice President of Business Development...
Total Annual Compensation: $398.8K
Vice President of Clinical Development
Total Annual Compensation: $419.7K
Vice President of U S Operations and General ...
Total Annual Compensation: $369.9K
Compensation as of Fiscal Year 2013.

vivus inc (VVUS) Key Developments

VIVUS Inc. Announces Resignation of Samuel F. Colin, M.D. to the Board of Directors

On January 22, 2015, Samuel F. Colin, M.D. notified VIVUS Inc., of his decision to resign from the Company's Board of Directors, effective immediately.

VIVUS, Inc. Appoints Svai S. Sanford as Chief Financial Officer

Svai S. Sanford has served as the interim Chief Financial Officer of VIVUS Inc., since November 2013 and the Chief Accounting Officer of the company since December 2013. On January 7, 2015, the Board of Directors of the company determined to remove the interim from Mr. Sanford’s title, such that Mr. Sanford’s title became the company’s Chief Financial Officer and Chief Accounting Officer effective January 7, 2015. Mr. Sanford, age 45, served as Corporate Controller from July 2012 until November 2013. Prior to this, Mr. Sanford was the Corporate Controller at Glam Media Inc., from November 2010 to June 2012, and in addition to other senior management roles within the company, he was the Senior Director, Technical Accounting, Reporting and Compliance at Elan Pharmaceuticals Inc., from March 2004 to November 2010.

VIVUS Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM

VIVUS Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $2.64 USD -0.08

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.56 USD -0.21
GlaxoSmithKline Consumer Healthcare Ltd 5,630 INR +3.80
GlaxoSmithKline PLC 1,490 GBp -7.00
Roche Holding AG SFr.252.80 CHF +1.10
View Industry Companies

Industry Analysis


Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at